Management of adverse events in TB care and active TB drug safety monitoring.
Tuberculosis (TB) remains the leading cause of death from a single infectious agent, with 10.8 million cases reported in 2023. While treatment is generally effective, both drug-susceptible (DS-TB) and drugresistant TB (DR-TB) regimens are associated with adverse events (AEs) that compromise adherenc...
| Publicado en: | Breathe Vol. 22; no. 1; pp. 1 - 11 |
|---|---|
| Autores principales: | , , , , , |
| Formato: | tables/charts Journal Article |
| Publicado: |
European Respiratory Society
Jan2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=191578834&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 191578834 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 18106838 85SQ jtl: Breathe issn: 18106838 maglogo: N pubinfo: dt: Jan2026 vid: 22 iid: 1 pid: 76609 pub: European Respiratory Society artinfo: ui: 191578834 191578834 191578834 10.1183/20734735.0203-2025 191578834 ppf: 1 ppct: 10 formats: fmt: @attributes: type: P tig: atl: Management of adverse events in TB care and active TB drug safety monitoring. aug: au: Ma'aruf, Shamsuddeen Yusuf Sharma, Aparna Fox, Shannon Duarte, Raquel Lange, Christoph Tiberi, Simon affil: Department of Medical Laboratory Science, Faculty of Allied Health Science, Kaduna State University, Kaduna, Nigeria sug: subj: Adverse Health Care Event Tuberculosis Drug Monitoring Patient Safety Physician Attitudes Hepatotoxicity Arthralgia Optic Neuritis Muscle Pain Linezolid Machine Learning Biological Markers Pharmacovigilance Algorithms Digital Health Diffusion of Innovation Patient Centered Care Manuscripts World Health Organization Pharmacogenetics ab: Tuberculosis (TB) remains the leading cause of death from a single infectious agent, with 10.8 million cases reported in 2023. While treatment is generally effective, both drug-susceptible (DS-TB) and drugresistant TB (DR-TB) regimens are associated with adverse events (AEs) that compromise adherence and outcomes. In this viewpoint, we highlight the most clinically relevant AEs: hepatotoxicity, cutaneous reactions and ocular toxicity in DS-TB; and linezolid-associated neuropathy, myelosuppression, QT prolongation and hepatotoxicity in DR-TB. We argue that structured safety monitoring and integration of active TB Drug Safety Monitoring and Management into routine care are critical to improving patient safety. Looking ahead, pharmacogenomics, therapeutic drug monitoring, predictive algorithms and digital health solutions offer opportunities to move from reactive to proactive AE management. By prioritising monitoring, innovation and patient-centred approaches, TB programmes can reduce the burden of AEs, improve adherence and achieve better outcomes. pubtype: Academic Journal doctype: tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|